Moreover, our data suggested that the downregulation of granulocyte/macrophage colony-stimulating factor (GM-CSF) may contribute to the pathogenesis of PCP in immunocompromised hosts, which provides insights into designing therapeutic strategies for immunocompromised patients by targeting macrophages. The gene discussed is CSF2; the disease is pneumocystosis.